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Abstract The presence of a large number of fibroblast growth
factors (FGFs) and multiple splice forms of their receptors
(FGFRs) in higher vertebrates makes the three-dimensional (3D)
analysis of FGF interactions with their receptors a formidable
task. The situation differs in Caenorhabditis elegans (worm) and
Drosophila melanogaster (fruit fly), where only one or two FGF
and FGFR sequences have been identified. Structural studies of
the FGF^FGFR complexes in such primitive organisms should
reveal the basic features of the ligand^receptor interactions as
they first emerged through evolution. We have analysed the
sequences of worm and fly FGFs and FGFRs and used the
recently determined crystal structure of the human FGF1^
FGFR2^heparin ternary complex [Pellegrini, L., Burke, D.F.,
von Delft, F., Mulloy, B. and Blundell, T.L. (2000) Nature 407,
1029^34] to construct 3D models of the homologous complexes.
In spite of a low sequence similarity with their human counter-
parts, key structural features required for ligand^receptor and
protein^heparin binding in humans are conserved in the fly and
worm FGF^FGFR^heparin complexes. Analyses of the models
show that tertiary interactions that are not conserved in sequence
are maintained through novel interactions or complementary
mutations in the fly and worm sequences. The overall charge
distributions observed in the human FGF^FGFR^heparin com-
plex are retained in the fly and worm models. The arginine
residue at position 253 in the linker region between the Ig-like
domains D2 and D3 in the wild type fly and worm sequences is
particularly striking, as the Pro253Arg mutation in humans is
responsible for Apert syndrome. This change may enhance the
affinity of receptors for their FGF molecules as observed in Apert
mutants. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Fibroblast growth factors (FGFs) comprise a large family
of growth factors that are key regulators of cell proliferation,
migration and di¡erentiation [2^4], with vital roles not only in
normal development and wound healing [5^9], but also in
tumour development and progression [10]. FGF receptors
(FGFRs) consist of up to three extracellular immunoglobulin
(Ig)-like domains (D1, D2 and D3), a single transmembrane
chain and an intracellular domain with tyrosine kinase activity
[11]. Upon FGF binding and receptor dimerisation, the kinase
domains of FGFRs undergo cross-phosphorylation, resulting
in signal transduction and biological response [12^14]. The
integrity of these developmental pathways requires extremely
tight regulation of FGF activity [15^19], and the essential
presence of heparin or heparan sulphate for the formation
of an active FGF signaling complex [20^32].
Twenty-two FGFs and several FGFR splice variants, aris-
ing from alternative mRNA splicing of four genes, have been
found in humans, and a similar variety of FGFs and their
receptors is widespread in the animal kingdom. However, in
the Caenorhabditis elegans genome, there are only two identi-
¢ed FGF homologues (egl17 and let756) and one FGFR se-
quence (egl15). Let756 was detected from the sequence data
[33], while egl15 and egl17 were characterised by genetic and
biochemical screens on the egg-laying defective (egl) mutants,
implicating them in sex myoblast migration during develop-
ment [34,35]. In the Drosophila melanogaster genome, one
FGF homologue [15] and two FGFR proteins, DFR1 and
DFR2 [36], have been described.
The recently published crystal structures of the human ter-
nary complexes FGF1^FGFR2^heparin [1] and FGF2^
FGFR1^heparin [37] exhibit both common and unique fea-
tures. The former (PDB code: 1e0o) is a co-crystallised 2:2:1
ternary complex, and the latter structure (PDB code: 1fq9) a
2:2:2 complex resulting from soaking of heparin fragments in
FGF2^FGFR1 crystals. Interestingly, the two structures share
common heparin^protein interactions (Fig. 1). However, in
1e0o, heparin bridges the two 1:1 FGF:FGFR complexes,
but in 1fq9 it is directly involved in receptor^receptor dimer-
isation. The di¡erences in the relative orientation of the do-
main D3 of the receptor may be induced by heparin binding
[1].
The structure of the human FGF^FGFR^heparin complex
allows us to consider whether the homologues in D. melano-
gaster and C. elegans can form similar ternary complexes.
The comparative modeling studies on the FGF^FGFR^hep-
arin complexes described here indicate a conserved heparin-
binding pocket, consistent with the observation that heparan
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sulphate has a direct role in FGFR activation in D. melano-
gaster development [20]. The models suggest that the key
determinants for FGF and heparin binding are retained in
the £y and worm sequences, although speci¢c amino acid
interactions observed in the human structure may not be con-
served between the FGFRs and their ligands.
2. Materials and methods
The alignment of the FGF and FGFR sequences from D. mela-
nogaster and C. elegans with the human sequences present in the
structure of Pellegrini et al. [1], was performed using the programs
FUGUE [38], CLUSTALW [39], SEAVIEW [40] and JOY [41]. These
alignments were used as input to Modeller4 [42,43] to generate initial
three-dimensional (3D) models of the FGF^FGFR^heparin com-
plexes, with the heparin coordinates from 1e0o. The template struc-
ture 1e0o has 15 disordered residues in each of its receptor chains and
the corresponding regions in the £y and worm sequences were omitted
during modeling. The program CODA [44] was used to remodel the
loop conformations and the side chains for these remodeled loops
were built by SCWRL [45]. The graphical software packages ‘O’
[46] and Swisspdb Viewer [47] were employed to check appropriate
rotamer conformations of the side chain atoms, in order to optimise
possible interactions. The models were then subjected to another
round of energy minimisation using Modeller4 and further assessed
by examining the JOY formatted sequences (Fig. 1), aligned on the
basis of their structures using the program COMPARER [48]. The
¢nal models were also checked for geometrical acceptability with the
programs PROCHECK [49] and VERIFY3D [50]. The program
CONTACT in the CCP4 package [51] was used to identify atoms
involved in protein^heparin and protein^protein contacts. The cut-
o¡ distance for hydrogen bonding or hydrophobic contacts was set
to 4.0 Aî , to accommodate all plausible interactions.
3. Results and discussion
3.1. Analysis of sequences and 3D models
Although the sequence identities between the human, £y
and worm sequences are in the range 22^35% (Table 1),
many of the residues previously reported as completely con-
served within the FGF and FGFR family [52] are also present
in the £y and worm sequences. This allowed models of the £y
and worm complexes to be constructed with good geometry,
and PROCHECK showed that more than 90% of residues for
each model were within the allowed regions of their P^i space
[49]. The values of the root mean square deviations (RMSD)
of the C-K superposition of the £y and worm models with
1e0o (Table 1), indicate that the core structures in the models
are well conserved. In Fig. 1, the residue numbering refers to
the models as FGF^DFR1^heparin (Fly1), FGF^DFR2^hep-
arin (Fly2), Egl17^egl15^heparin (Worm1), let756^egl15^hep-
arin (Worm2) and the template human ternary complex
(1e0o). However, in all ensuing discussions we follow the res-
idue numbering used in the template X-ray structure (1e0o),
i.e. ligand: 10^138; FGFR-D2: 149^250; linker region: 251^
254; FGFR-D3: 255^360.
Alignment with all currently available FGF sequences
showed that the residues that are absolutely conserved [52]
are retained in let756 and the £y FGF. However in egl17
the invariant M67 is replaced by phenylalanine and G71 by
alanine. The substitution of a large hydrophobic side chain in
place of methionine is easily accommodated in the core of the
ligand. Other features of egl17 include the presence of ¢ve
tryptophan residues and a higher percentage of basic residues
in the core region.
3.2. Receptor^ligand interactions
Analyses of the receptor^ligand contacts in Fly1, Fly2,
Worm1 and Worm2 complexes suggest that they are likely
to be similar to those of human homologues [1,53,54]. A total
of 32 residues are involved in di¡erent types of interactions
across the interfaces of ligand^receptor complexes in 1e0o,
and between 13 and 18 of these interactions are conserved
between the models and the template structure 1e0o. The res-
idues involved in equivalent ligand^receptor contacts in the
models are listed in Table 2.
Interactions between the FGF and FGFR domain D2 are
primarily hydrophobic, involving the residues aligned with
Y15, Y94, L133, P134, L135 in the ligand and L166, A168
and P170 in the receptor. Contacts between the ligand and
Table 1
Percentage identities among the sequences and the RMSD between
their K-carbon positions in various models
RMSDs PIDs
1e0o Fly1 Fly2 Worm1 Worm2
1e0o ^ 32.9 29.7 27.3 35.0
Fly1 0.87 ^ 62.1 23.5 31.1
Fly2 0.99 0.96 ^ 22.1 29.8
Worm1 0.88 0.93 1.20 ^ 68.4
Worm2 0.43 0.98 1.05 0.97 ^
Table 2
Residues in various models involved in equivalent interactions
across ligand^receptor interfaces (residues marked with * indicate a
possibility of an interaction equivalent to that seen in 1e0o)
1e0o Fly1 Fly2 Worm1 Worm2
Molecule A
Y15 Y6 Y6 F6 F6
R37 E26 E26 K29 E36
V51 V40 V40 D42 M50
L89 M78 M78 V81 M90
Y94 Y83* Y83* F86 Y95
L133 Y125 Y125 L125 L136
P134 T126 T126 V126 V137
L135 N127 N127 R127 V138*
Molecule B
L166 L147 L141 T150 T161
A168 T149 H143 A152 A163
P170 P151 L145 P154 P165
D247 I225 Q216 I232 I243
R251 R229 R220 R236 R247
I257 I235 I226 I242 I253
I350 Q315 R312 M327 M338
Molecule C
Y15 Y331 Y328 F344 F355
S17 K333 K330 E346* R357
R35 Q349 Q346 P365* K383
L89 M403 M400 V419 M439
E90 G404 G401 R420 M440
N92 Q406 Q403 N422 N442
H93 N407 N404 F424 Y443
L133 Y450 Y447 L463 L485
Molecule D
R165 F471 R462 E487 E509
L166 L472 L463 T488 T510
A168 T474 H465 A490 A512
V169 R475 S466 L491 L513
P170 P476 L467 P492 P514
R251 R554 R542 R574 R596
R255 K538 A546 P578 P600
I257 I560 I548 I580 I602
Molecules A and C = FGFs; Molecules B and D = FGFRs.
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domain D3 are also hydrophobic with a well conserved inter-
action between V51 and I350. Involvement of R255 (in D3) in
an electrostatic interaction with an invariant glutamate (E87)
in the ligand has been demonstrated to be important, as a 10-
fold reduction in receptor binding a⁄nity is observed when
this glutamate is mutated to glutamine [55]. The absence of
this charge^charge interaction in the Fly2 and worm models,
chie£y due to substitutions in position 255, could suggest an
alternate mode of binding and a di¡erent orientation of do-
main D3. However, an interaction with a substituted lysine at
position R255 in Fly1 appears feasible.
There exist some di¡erences with potential functional con-
sequences in the residues linking the domains D2 and D3 (Fig.
1). Two point mutations in FGFR2, S252W or P253R, have
been shown to be responsible for the vast majority of cases of
Apert syndrome, a human congenital condition characterised
by craniosynostosis and severe syndactly of the ¢ngers and
toes [13,56]. In vitro studies [57,58] on mutant receptors
have shown increased ligand^receptor a⁄nity, a broadening
of receptor speci¢city, and an increased lifespan of the ligand^
receptor complex. Intriguingly, the £y and worm receptors
have an arginine at the position equivalent to P253, a feature
of Apert [13], Pfei¡er [59] and Muenke [60] syndromes, which
could have implications for the a⁄nity of the receptor for
ligand in the £y and worm complexes and may provide better
stabilising interactions with the FGF ligand [57,58].
The network of interactions of the invariant R251 in the
linker region gains signi¢cance as mutagenesis data on a li-
gand residue (N95A) reveal a 400-fold reduction in receptor
a⁄nity [61]. In the human complex 1e0o, the guanidinium
moiety of invariant R251 in the linker between domains D2
and D3 is surrounded by three hydrophobic ligand residues
L89, L133 and P134, and is hydrogen bonded to the main
chain oxygen of H93 and the side chain oxygen of N95 [1].
The sequence alignment (Fig. 1) indicates the conservation of
this asparagine in £y and let756 ligands, while it is substituted
to a serine in egl17. However, a similar network of interac-
tions is retained in both the £y and worm models. In Fly1 and
Fly2, the invariant arginine residue equivalent to R251 makes
a strong hydrogen bond with a threonine residue, present in
the position equivalent to P134, while the neighbouring as-
paragines, equivalent to H93 and N95, appear to maintain
the interaction geometry. The methionine and tyrosine resi-
dues aligned at positions L89 and P133 may well contribute to
equivalent hydrophobic interactions. Likewise in the worm
models, the invariant residue at R251 makes very similar hy-
drogen bonds with ligand residues in positions equivalent to
H93 and N95. The hydrophobic interactions rendered by L89,
L133, and P134 appear well maintained by the equivalent
residues in the worm ligands. Thus, the common features
between ligand^receptor interactions observed in £y and
worm models and those in the human receptor complex sug-
gest a similar mode of recognition.
3.3. Protein^heparin interactions
The X-ray structure of the human FGF1^FGFR2^heparin
ternary complex [1] reveals that the heparin decasaccharide
mediates the dimerisation of two 1:1 ligand^receptor com-
plexes, lying between and interacting with both FGF mole-
cules and one receptor molecule. A range of basic and polar
residues in FGF and FGFR constitute the binding sites for
heparin (Table 3). The analysis of equivalent heparin-binding
residues in the D. melanogaster and C. elegans sequences in-
dicates high similarity. Residues that are involved in interac-
tion with the heparin molecule in the models of 1e0o, Fly1,
Fly2, Worm1 and Worm2 respectively are highlighted in Fig.
1 and listed in Table 3.
A total of 25 residues in 1e0o interact with the heparin
molecule. In both models of Fly1 and Fly2, 30 residues
were identi¢ed as interacting with heparin. Of these, 16 resi-
dues in 1e0o, 22 in Fly1 and 24 in Fly2 interact by forming
hydrogen bonds, the majority of which (14 in 1e0o, 11 in Fly1
and 10 in Fly2) are basic residues. The remaining residues are
involved in hydrophobic contacts. Likewise, 27 and 26 resi-
dues interact with the heparin molecule in Worm1 and
Table 3
Residues in equivalent positions interacting with the heparin mole-
cule in various models
1e0o Fly1 Fly2 Worm1 Worm2
Molecule A
^ K8 K8 ^ ^
N18 N9 N19 Q11 S9
^ ^ Y99 ^ ^
^ L100 ^ ^ ^
K112 A101 A101 N102 R115
K113 L102 L102 G103 R116
N114 N103 N103 R104 S117
^ ^ ^ R106 ^
^ Q107 Q107 ^ ^
^ P108 ^ ^ ^
K118 R109 R109 Q108 R121
R119 R110 R110 N109 R122
^ ^ ^ Y113 ^
R122 I113 I113 H114 N125
G126 R117 R117 R118 R129
Q127 S118 S118 C119 R130
K128 L119 L119 F120 K131
A129 G120 G120 D121 A132
Molecule B
^ K142 ^ ^ ^
K161 K143 ^ N143 N154
^ ^ E137 ^ ^
K164 ^ K139 ^ ^
H167 Q148 Q142 H151 H162
^ ^ N148 R157 ^
T174 L155 T149 T158 T169
V175 L156 V150 L159 L170
K176 T157 N151 K160 K171
^ ^ ^ ^ R175
R178 ^ ^ N162 ^
^ K188 ^ ^ ^
^ R191 ^ ^ ^
I217 ^ R186 ^ ^
^ ^ ^ ^ E213
Molecule C
^ ^ ^ R399 ^
^ ^ ^ R401 K420
K105 A419 A416 ^ R455
^ R420 R417 ^ ^
W107 R421 R418 ^ W459
K112 ^ ^ ^ R464
^ ^ ^ R442 ^
^ ^ ^ ^ K468
^ ^ Q429 ^ ^
^ P433 ^ ^ ^
^ ^ R431 ^ R471
R119 R435 R432 L449 ^
^ ^ ^ S450 ^
P121 Q437 Q434 Y451 P473
R122 I438 I435 H452 N474
Molecules A and C = FGFs; Molecule B = FGFR (heparin does not
interact with Molecule D).
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Fig. 3. Illustration of the charge pro¢le of heparin-binding pocket in ternary complexes of 1e0o (A,B), Fly2 (C,D) and Worm1 (E,F). Heparin
is depicted by rods. Images created by GRASP [71].
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Worm2, respectively. Of these, 8 and 14 residues respectively
are basic in nature. Fig. 2, generated by LIGPLOT [62], sche-
matically illustrates these interactions between the basic resi-
dues and the heparin decasaccharide in the Fly1 and Worm2
models. Most dramatically, the overall charge distributions
found in the human complexes are conserved in the £y and
worm models (Fig. 3), especially in proximity to the heparin-
binding pocket. This suggests that FGFs and FGFRs in
D. melanogaster and C. elegans have binding sites for heparin
similar to those observed in the human complexes.
Site-directed mutagenesis and other in vitro studies have
identi¢ed speci¢c residues that contribute signi¢cantly to hep-
arin binding [21,31,63]. The interaction of a ligand residue,
K125, in human FGF2 (its equivalent residue being K118 in
1e0o) is reported to be important in heparin binding as its
mutation to an alanine leads to a 20% loss in binding energy
[64]. Heparin interactions through the equivalent ligand resi-
due in the £y (R109), let756 (R122) and egl17 (Q108) appear
structurally maintained. Studies on the human receptor do-
mains (FGFR1) have revealed an 18-residue peptide (K18K)
that forms an obligatory heparin-binding domain [22], which
corresponds to the amino acid stretch between K161 and
R178 in 1e0o (Fig. 1). The heparin^receptor interactions in
these equivalent stretches in D. melanogaster and C. elegans
models also exhibit high similarity (Fig. 1 and Table 3).
Thus, the overall features of the interactions of FGF and
FGFRs with heparin appear to be well conserved even in
these primitive species, although the sequence identities with
human homologues are as low as 30%. Table 3 shows that,
although there are a number of substitutions of residues which
interact with heparin in the human structure, there should be
reasonable compensation in both the number and nature of
interactions, thus preserving the overall a⁄nity for heparin
with species variation.
4. Conclusions
Comparative modeling studies on the D. melanogaster and
C. elegans FGFs and their receptor sequences indicate that
they can adopt similar conformations and make equivalent
interactions to those observed in corresponding human struc-
tures. The analyses of heparin^protein contacts reveal a con-
served binding surface for heparin in their FGFs and FGFRs.
The similarity of the protein interface, particularly with re-
spect to its charge distribution also suggests similar dimerisa-
tion and signaling mechanisms in these primitive organisms.
Whilst D. melanogaster and C. elegans maintain only a
small number of FGFs and FGFRs, mammals exhibit a broad
range of ligands and receptors. This may be related to the
development of bone structures, and the highly developed
immune and neuronal systems in vertebrates. Although there
is no evidence for FGF involvement in immune development,
multiple mutations have been documented which cause devel-
opmental defects in the skull, the long bones, and the digital
bones [65^67]. Recently, several FGFs have been localised to
speci¢c subsets of neuronal tissues in the mouse brain [68^70].
These data support the hypothesis that FGFs are heavily in-
volved in the correct formation of bone and complex neuronal
structures, and it is possible that the increase in FGF numbers
correlates with greater neuronal and skeletal complexity. It
has been shown that some mutations found in Apert syn-
drome and other related disorders lead to an increase in re-
ceptor a⁄nity and a broadening of speci¢city [57,58]. It is
possible that £y and worm FGFRs developed similar features
early in evolution, and that decreased a⁄nity and increased
speci¢city were a necessary prerequisite for subsequent diver-
si¢cation of roles of receptors and ligands.
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